OnKure Therapeutics advances next-gen PI3Kα inhibitors, closes $150M funding to push clinical trials in 2027

OnKure Therapeutics reported Q1 2026 results highlighting the nomination of two next-generation PI3Kα pan-mutant selective inhibitors, OKI-355 for vascular anomalies and OKI-345 for breast cancer. The company secured $150 million in private placement funding to support clinical development planned for 2027, with $192 million cash on hand expected to fund operations through 2029. OnKure is focusing on these inhibitors to provide targeted therapies with fewer toxicities and plans to submit IND applications to the FDA in the first half of 2027. The company also announced it will not independently pursue further development of OKI-219, another PI3Kα inhibitor, shifting focus to the new candidates.